

Peptide-Based Vaccines for Neurodegenerative Diseases

Subjects: [Immunology](#) | [Neurosciences](#)

Contributor: Evangelia Livaniou

Neurodegenerative diseases are associated with a progressive loss of neurons in the central nervous system (CNS) and are characterized by severe clinical deficits, especially cognitive, motor, and psychiatric ones. The most common neurodegenerative disease is Alzheimer's disease (AD), while other well-known neurodegenerative diseases include Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), etc. During the last two decades several research endeavors have been devoted to the development of peptide-based active immunotherapies/vaccines for fighting neurodegenerative diseases -aiming, eventually, at clinical application. The most significant among the aforementioned peptide-based candidate vaccines for neurodegenerative diseases have been based on specific epitopes of certain biomolecular targets associated with neurodegeneration, especially beta-amyloid peptide (A β), tau protein (tau) and α -synuclein (α -syn), as will be presented below.

vaccines

neurodegenerative diseases

peptide epitopes

beta-amyloid-based peptide-vaccines

tau-protein-based peptide-vaccines

α -synuclein-based peptide-vaccines

1. Treatment of AD and other Neurodegenerative Diseases: Short History

AD and other neurodegenerative diseases ^[1] have a high socioeconomic impact. Treatment of AD is a very important issue for health care systems worldwide ^[2]. Until recently, treatment for AD patients relied on the pharmacological intervention of cholinergic and glutamatergic neurotransmission. Thus, a few drugs for AD have been approved by the US Food and Drug Administration (FDA), including donepezil, rivastigmine, and galantamine (cholinesterase inhibitors), memantine (an N-methyl-D-aspartate receptor partial antagonist), and a combination of donepezil and memantine. All these drugs, however, have limited effectiveness and they do not reverse the progression of the disease or improve cognitive dysfunction, but they rather delay the deterioration of AD symptoms for a limited time period ^[3]. In 2021 a passive immunotherapeutic agent, i.e. a fully human monoclonal antibody was approved by the FDA as a treatment for AD, but some controversy has surrounded this decision ^{[4][5][6][7][8]}. Overall, investigation and development of more successful therapeutic/preventive strategies to fight AD and other neurodegenerative diseases is still a goal of utmost importance ^[9]. Several research endeavors have been focused on the development of peptide-based active immunotherapies/vaccines for neurodegenerative diseases ^{[10][11]} and this approach seems to be an interesting perspective in the field.

2. Biomolecular Targets of Vaccines for Neurodegenerative Diseases

Significant efforts toward the development of active immunotherapies/vaccines for neurodegenerative diseases have focused on targeting pathologic species of A β , tau, and, to a lesser extent α -syn since aberrant aggregation of these biomolecules is considered to play a major role in the disease pathophysiology [12]. Immunization targeting these peptides/proteins has been expected to result in the generation of antibodies that might facilitate clearance or prevent the formation of neurotoxic forms of the parental targets [10]. However, there are some issues that should be taken into account and appropriately addressed, in order to achieve optimal results: A β , as well as tau and α -syn, are probably conceived as “self” molecules by the host organism; thus, they may be either non-immunogenic or induce a detrimental auto-immune reaction [2] and this aspect should be carefully taken into consideration when designing such a vaccine. Another issue is how the antibodies induced after immunization can cross the blood–brain barrier and access the pathologic spots [10]. However, antibodies against A β that had been peripherally administered were reported to enter CNS in mouse models of AD, and in human subjects participating in clinical trials [2][13]. In vivo access of the pathologic loci is even more complicated, when intracellular proteins are targeted, such as tau. Previous experimental data have shown, however, that intracellular “neurodegenerative” proteins may be also present extracellularly [14]. Moreover, recent technological advances, especially in the field of formulation/delivery systems, have facilitated successful in vivo accessibility of pathologic targets and stimulated new efforts to develop active immunotherapies targeting A β , tau, and α -syn [14].

According to recently accumulated evidence, neurotoxic species of A β , tau, and α -syn may exert their toxicity at least in part through binding to cellular prion protein (PrP) on the surface of neurons [15][16][17]. Thus, PrP rather than individual disease-associated proteins might be (immuno)therapeutically targeted. Moreover, a few additional molecular targets have been reported in the literature, e.g., TAR DNA-binding protein 43 (TDP-43), dipeptide repeat proteins (DPRs), superoxide dismutase 1, and huntingtin protein [1][14][18][19][20], but little data on the development of vaccines against these targets are currently available.

3. Peptides Epitopes: General Concepts

Peptide vaccines are based on specific B- (and T-) cell peptide epitopes. The epitope choice is a crucial step in the vaccine design, since the peptide epitopes should be able to induce strong, long-lasting humoral and/or cellular immunity against the biomolecular target [21].

A B-cell epitope is a specific fragment of the antigen/immunogen which is recognized by the B-cell receptors present on the surface of B-cells of a unique clone; B-cell epitopes are subsequently bound to the antibodies generated upon B-cell stimulation/maturation. B-cell epitopes can be linear and may be as short as pentapeptides, but they are mostly conformational [11][22]. T-cell epitopes are linear peptide fragments that can be bound to major histocompatibility complex proteins (MHC I, MHC II), through which they are presented on the surface of appropriate cells and subsequently recognized by T-cell receptors on CD8+ (cytotoxic T-cells) and CD4+ (helper T-

cells), respectively [11][22]. Cytotoxic T-cell epitopes are usually 8- to 12-mer peptides, whereas helper T-cell epitopes (Th) are usually 12- to 17-mers [2][22].

Identifying epitopes in disease-associated immunogens is of great interest for designing epitope-based vaccines. NMR and X-ray crystallographic methods have been used for this purpose. T-cell and B-cell epitope computational prediction methods and tools (immunoinformatics), which are faster and less expensive than NMR and X-ray crystallography, have also been employed [22][23][24]. Moreover, antibodies have been often utilized as a template for vaccine design, following the concept that if a particular epitope is related to certain B-cell responses, then it will probably induce similar responses when administered in the form of a vaccine [10].

4. Peptide Epitopes Used in A β -Vaccines

The first therapeutic approach for AD through active immunization was based on full-length pre-aggregated A β (1-42) [25]. However, the first clinical trials with the so-called AN1792 vaccine (**Table 1**), based on A β (1-42), failed, since meningoencephalitis appeared in some of the immunized AD patients; this severe side-effect was attributed to a cell-mediated inflammatory response caused by the T cell epitopes of A β (1-42) -and also the adjuvant used (QS-21). Moreover, the AN1792 vaccine induced rather insufficient antibody titer, probably due to the weak immunogenicity of A β [2][9][26].

Despite the serious safety issues and the rather low efficacy, results of the initial clinical trials with AN1792 along with follow-up data inspired further research toward the development of vaccines targeting A β . Special efforts were focused on how to avoid autoreactive T cells against A β and to generate relatively high titers of antibodies. Biochemical assays have identified the first N-terminal 15 amino acids of A β as the site of the principal B-cell epitope [27], whereas the T-cell epitopes are believed to localize in the C-terminus. Thus, second-generation A β vaccines were developed by selecting peptide fragments of the N terminus of A β , and suitably formulating [28] these fragments with foreign carriers/delivery systems and adjuvants, so as to enhance the immunogenicity of B-cell epitopes [2][10].

Second-generation A β vaccines that have subsequently been tested in clinical trials (**Table 1**) include CAD106, ACC-001 (vanutide cridificar), Lu AF20513, UB-311, ACI-24, V-950, ABvac40, AD01, AD02, and AD03 [2][9][10][14][28][29]. CAD106 [1][2][9][10][14][28][29][30][31] is based on the first 6 amino acids of A β , ACC-001 [1][2][9][14][28][29][32] is based on the first 7 amino acids, Lu AF20513 [2][9][10][28][29] is based on the first 12 amino acids, UB-311 [2][9][10][14][28][29][33] is based on the first 14 amino acids, and ACI-24 [1][2][9][14][28][29] is based on the first 15 amino acids, whereas V-950 also employs an N-terminal A β peptide fragment [9][28][29], reported to be A β (1-15) [33]. On the other hand, it should be noticed that ABvac40 vaccine [1][2][9][10][14][28][34] has employed a short C-terminal fragment of A β , i.e., A β (33-40), based on the observation that antibodies raised against the C-terminus of A β seem to affect A β aggregation [34][35]. Moreover, AD01 [9], AD02 and AD03 [2][9][14][28][29][36] are based on epitopes mimicking the A β N-terminus [9][29]. Though none of the second-generation vaccines have induced meningoencephalitis, a few antibody-mediated adverse effects did appear, while these vaccines could not lead to a dramatically improved

therapeutic outcome [37]; therefore, clinical trials have continued only for a few of them, i.e., CAD106, ACI-24, UB-311, and ABvac40, as recently reported [2].

In addition to vaccines that have undergone clinical trials, many other peptide-based A β -vaccines have been developed and tested in rodents, mostly transgenic mice. Most of these vaccines focus on the A β N-terminus. More specifically (**Table 1**), A β (3-10) [37][38][39] and A β (1-6) were among the peptide epitopes used [40]; different copy numbers of the latter were used in another attempt to develop new A β -vaccines [41]. In addition, A β (1-6) and A β (1-15) were used for the synthesis of 4-branched multiple-antigen peptides (MAP)4 and subsequently administered to mice to develop A β specific antibodies [42]. A β (1-15) was also used in a cholera toxin B subunit/silkworm pupa vaccine [43] as well as in a yeast-based vaccine (Y-5A15) [44]. A β (1-11) was used in a combination vaccine (AV-1959R/AV-1980R) targeting both A β and tau [45]. Moreover, A β (1-11) was used in a DNA vaccine (AB-1959D), which encoded for a fusion protein containing three copies of A β (1-11) [46]. A β (1-11) was also part of a fusion protein containing the bacterial protein domain E2, (1-11)E2, which was further used in animal vaccination [47]. Vaccines based on small cyclic peptides, i.e., cyclo[A β (22-28)-YNGK'], cyclo[A β (23-29)-YNGK'], and cyclo[A β (22-29)-YNGK'], mimicking the specific molecular turn in the structure of oligomeric A β were reported [48]. In a recent paper, a series of several synthetic A β epitope-peptides, linear or cyclic, including A β (1-6), A β (1-6)3, A β (1-15), cyclo[A β (1-7)], cycloEP1 and cycloEP2 (where EP1 and EP2 are special peptide epitopes of A β oligomers, selected with phage display from random peptide libraries), have been appropriately formulated and subsequently tested in animal preclinical studies [49]. Interestingly, intact A β (1-42) was specially formulated and tested in animals a few years ago, without inducing neuroinflammation [50]. Moreover, a DNA vaccine based on A β (1-42) trimer and targeting amyloid plaques and tau protein was also reported [51]. Since soluble A β oligomers and protofibrils are now considered as the most toxic forms of A β and the ideal target of an A β -vaccine may be a discontinuous conformational epitope formed by soluble A β oligomers [18][28][35], one more vaccine (AOE1) based on specific conformational epitope(s) of A β oligomers has been recently described [52].

5. Peptide Epitopes Used in Tau-Vaccines

Targeting therapeutically relevant epitopes on tau proteins in a safe manner is a very interesting and highly challenging objective [53]. Identification of the most effective tau epitopes for vaccine development is still a matter of debate since many modifications of tau, mainly phosphorylation along with truncation, oligomerization, etc., have been demonstrated to contribute to neurodegenerative disease pathogenesis. Moreover, it should be noticed that tau contains more than eighty potential serine, threonine, and tyrosine phosphorylation sites, while many phosphorylated epitopes of tau are also present in healthy human brains; which epitope will be chosen and targeted is therefore very critical [54][55].

Two tau vaccines have been tested in clinical trials with AD patients, AADvac1 and ACI-35 (**Table 1**). AADvac1 [1][9][10][14][28][54][56][57][58] is based on tau(294-305). This sequence was approximated through experimental immunization of transgenic mice with mis-disordered tau(151-391/4R) followed by isolation of antibodies and screening for in vitro disruption of tau-tau interaction [10]; tau(294-305) epitope was determined by X-ray crystallography [59] and then tested in an AD-animal model [60]. AADvac1 induces specific antibodies targeting three

or four conformational epitopes on mis-disordered tau protein with an exposed microtubule-binding repeat domain (MTBR), which seems to be actively involved in tau aggregation [14][57][58]. Initial clinical trials have proved vaccine safety, thus encouraging further trials with larger numbers of participants [10]. On the other hand, vaccine ACI-35 [1][9][10][14][54][57] is based on the synthetic C-terminal peptide tau(393-408); more specifically, it consists of 16 copies of the aforementioned tau fragment, phosphorylated at Ser³⁹⁶ and Ser⁴⁰⁴ [10][53][57]. The rationale is that the antibodies induced will attack tau conformers containing the pathologic phosphorylation residues rather than the non-pathologic tau species [54]. A few years ago, a phase Ib/IIa trial was conducted to validate the safety, tolerability, and immunogenicity of an advanced version of this vaccine, i.e., ACI-35.030 [1][9][14].

In addition to the vaccines that have undergone clinical trials, other tau-vaccines have been developed and tested in animal preclinical studies (Table 1). More specifically, the N-terminal region tau(2-18), also known as phosphatase activating domain (PAD), has been appropriately formulated and used for vaccinating transgenic mice, since PAD becomes exposed in pathologic tau and plays an essential role in tau polymerization [45][61][62][63]. Moreover, the epitope tau(294-305), i.e., that used in vaccine AADvac-1, has been specially formulated (T294-HBcVLP) and the vaccine was tested in AD transgenic mice [64]. On the other hand, many vaccines recently tested in animals target phosphorylated tau (phospho-tau) epitopes [55][65][66][67]. Pathologic phosphorylation is a crucial event in tau pathogenicity and it is believed that by eliminating such toxic tau species, the degenerative process may be blocked [68]. Thus, a series of peptides from tau protein, including the so-called T294, pTau(396-404), and pTau422, have been used in a recent preclinical study; more specifically, two phosphorylated epitopes of tau, pTau(396-404) and pTau422, along with T294, i.e., tau(294-305), were appropriately formulated using the so-called SpyCatcher/SpyTag technology and administered to AD transgenic mice; as shown, the vaccine based on pTau422 peptide alleviated cognition deficits and blocked neuropathology progression in animals [49]. In another recent preclinical study, three phosphorylated tau peptides (pTau peptides) bearing a combination of up to four AD-related epitopes were designed and synthesized. pTau30 has been phosphorylated at residues Ser²⁰²/Thr²⁰⁵/Ser²³⁸/Ser²⁶²; pTau31 has been phosphorylated at residues Ser²⁰²/Thr²⁰⁵/Ser³⁹⁶/Ser⁴⁰⁴; pTau35 has been phosphorylated at Ser²³⁸/Ser²⁶²/Ser³⁹⁶/Ser⁴⁰⁴. Mice immunization has shown that only pTau31-induced antibodies could recognize all carried four epitopes. Furthermore, pTau31 could neither elicit non-phosphorylated Tau31-specific antibodies nor stimulate tau-specific T-cell activation [67]. Moreover, other tau peptides containing tauopathy-related phosphorylated epitopes, i.e., tau(195-213)/p202/205, tau(207-220)/p212/214, and tau(224-238)/p231, were used for animal vaccination in preclinical studies, leading to results supporting the alleviation of both, tau and Aβ pathologies [65]. Similarly, in a previous work, tau(379-408)/p396/404 was tested in preclinical studies leading to a reduction in both, tau and Aβ pathologies [1][69].

6. Peptide Epitopes Used in α-Syn Vaccines

In order to identify surface-exposed regions of in vitro and in vivo formed aggregates of α-syn, polyclonal IgY antibodies were raised against short linear peptides of α-syn and used in suitable immunochemical studies [70]; as revealed, the N-terminal α-syn(1-10) and C-terminal α-syn(90-140) fragments were surface-exposed [70] and may, therefore, be considered as putative epitopes of α-syn. Following a rather similar approach, the C-terminal

fragments α -syn(111-140)/ α -syn(121-140), which are recognized by human anti- α -syn antibodies isolated from PD patients [71], have also been considered putative epitopes of α -syn. On the other hand, the secondary structural features of α -syn in an aqueous environment have been studied with computer simulation [72], revealing information that may be exploited when new peptide-based α -syn-vaccines are to be designed.

The only α -syn vaccines that have been tested in clinical trials (**Table 1**) are based on short synthetic peptide fragments that mimic C-terminal residues of α -syn(110-130) (PD01A and PD03A, Affiris) [14][73][74][75][76][77][78]. PD01A and PD03A have shown promising efficacy and safety in phase I clinical trials with multiple system atrophy (MSA) patients. Interestingly, peptides from the C-terminus of α -syn have been reported to induce in vitro both helper and cytotoxic T cell autoimmune responses in patients with PD [79]; the still adequately good safety features of PD01A/PD03A, which target the α -syn C-terminus, may be attributed to two main reasons, (i) the C-terminal peptides used are too short for inducing a T-cell autoimmune response, and, (ii) the vaccines developed do not bear the exact native epitope, but rather a mimicking sequence [14][73][78]. In July 2021, the AC Immune Company announced that it would begin a phase II clinical trial of an optimized formulation of the PD01 vaccine, called ACI-7104 [78].

In addition to the aforementioned vaccines tested in clinical trials, other α -syn vaccines have been developed and evaluated in animal preclinical studies [80][81].

7. Future Perspectives - Conclusions

Future Perspectives: After two decades of research in the field, the development of successful peptide-based vaccines for neurodegenerative diseases seems to be a very ambitious, but not impossible goal to achieve. Further research on the design and selection of appropriate B-cell peptide epitopes of A β (including safe conformational epitopes of A β oligomers), tau, and α -syn, which would be capable of inducing antibodies of high titer and optimal features, and prevent any undesirable T-cell autoimmune responses, may eventually result in vaccines of great efficacy and safety. Moreover, using simultaneously multiple peptide epitopes of A β , tau, and α -syn may enhance the overall vaccine efficacy, in comparison with monotherapy, as several literature reports have pointed out [2][14]. Peptide-based vaccines targeting biomolecules other than A β , tau, or α -syn [1][14][18] may also prove to be successful, while combinations of vaccines and passive immunotherapies (antibodies) might be advantageous [14]. Research achievements in other related areas are expected to stimulate and greatly assist research toward novel peptide-based vaccines for neurodegenerative diseases. Thus, results of passive immunotherapy with anti-A β monoclonal antibodies are expected to provide valuable information concerning the immunochemical features, such as the epitope specificity and subclass that the vaccine-induced antibodies should ideally show [2]. Moreover, valuable information is expected to be gathered and exploited via numerous peptide-based vaccines, e.g. vaccines targeting acquired immune deficiency syndrome (AIDS), malaria, and, most recently, coronavirus disease 2019 (COVID-19 [11]), as well as peptide-based anti-cancer vaccines [82], which are currently under development. It should also be noted that promising new adjuvants have been recently proposed in vaccine research, including, interestingly, short peptides that target Toll-like receptors [83][84]. In addition, a deeper insight into less-studied risk factors for neurodegenerative diseases [85] and a better understanding of the biological mechanisms through which

nutritional, environmental, and lifestyle parameters may affect neuropathology (similar with their influence on pathology/epidemiology of, e.g., neoplastic diseases [86]), are expected to broaden the array of putative therapeutic targets for fighting neurodegeneration. On the other hand, preliminary findings that associate gut microbiome with brain diseases [87][88], e.g., PD, through several ways including the production of proteins similar to misfolded α -syn by the intestine microbes (which may further serve as a human-protein misfolding-template), are just an example of how diverse future perspectives in this area may be. Moreover, recent research efforts have focused on the discovery of novel biomarkers, eventually including personalized markers, for assessing onset and/or progression of neurodegenerative diseases [1][3][89], while much research has been directed toward developing improved analytical methods for reliable measurement of established biomarkers, each one alone or often in combination, in easily available biological fluids, such as plasma, urine, or saliva [1][90][91][92]. Thus, success in the discovery of novel biomarkers, especially in the area of synucleinopathies [14], and development of highly reliable and easy to perform methods for biomarker analysis will definitely facilitate the evaluation of candidate peptide-based vaccines for neurodegenerative diseases and accelerate further progress.

Conclusions: Neurodegenerative diseases are very complex and heterogeneous in nature, and their treatment remains a great challenge for the community. Interest in immunotherapeutic approaches has been rekindled after recent FDA-approval (even amid some controversy) of a monoclonal antibody as the first, passive, immunotherapy against AD. Efforts to develop active immunotherapies, i.e., vaccines, on the other hand, have actually never been abandoned, despite initial setbacks. The vast majority of vaccines under development are peptide-based ones and employ specific peptide epitopes (or, specially designed mimotopes) of biomolecular targets associated with the neurodegeneration onset/progress, such as the polypeptide A β , or the proteins tau and α -syn. The overall efficacy and safety of peptide-based vaccines are greatly influenced by specific factors, such as the exact peptide epitope and the formulation components used. Further advances, including the discovery of novel biomolecular targets linked with neurodegeneration, identification of peptide-epitopes on the former through high-resolution structural biology methods or immunoinformatics, and the development of improved formulation systems are expected to accelerate/facilitate research in this particulate area of immunotherapy, aiming ultimately at clinical exploitation.

Table 1. Peptide-based A β -, tau-, and α -syn vaccines for neurodegenerative diseases: Peptide epitopes and main formulation components used.

Target/Vaccine	Peptide Epitope	Carrier Protein/Delivery System	Adjuvant	Type of Study	Reference
A β /AN1792	A β (1-42)	Pre-aggregated peptide	QS-21	Clinical	[2][9][26][28] [29]
A β /CAD106	A β (1-6)	Q β -VLPs ¹	Alum or MF59	Clinical	[1][2][9][10] [14][28][29] [30][31]
A β /ACC-001	A β (1-7)	CRM197 ²	QS-21	Clinical	[1][2][9][14] [28][29][32]

Target/Vaccine	Peptide Epitope	Carrier Protein/Delivery System	Adjuvant	Type of Study	Reference
A β /Lu AF20513	A β (1-12)	Tetanus toxoid	-	Clinical	[2] [9] [10] [28] [29]
A β /UB-311	A β (1-14)	UBIth ³	Alum + CpG ⁴	Clinical	[2] [9] [10] [14] [28] [29] [33]
A β /ACI-24	A β (1-15)	Liposomes	MLPA ⁵	Clinical	[1] [2] [9] [14] [28] [29]
A β /V950	A β (1-15)	ISCOMATRIX	Quil A	Clinical	[9] [28] [29] [33]
A β /ABvac40	A β (33-40)	KLH ⁶	Alum	Clinical	[1] [2] [9] [10] [14] [28] [34]
A β /AFFITOPE AD01	A β N-terminus mimotope	KLH	Alum	Clinical	[9]
A β /AFFITOPE AD02	A β N-terminus mimotope	KLH	Alum	Clinical	[2] [9] [14] [28] [29] [36]
A β /AFFITOPE AD03	A β N-terminus mimotope	KLH	Alum	Clinical	[9] [29]
Tau/AADvac1	Tau(294-305)	KLH	Alum	Clinical	[1] [9] [10] [14] [28] [54] [56] [57] [58]
Tau/ACI-35	Tau(393-408) [p ⁷ 396/p404]	Liposomes	MLPA	Clinical	[1] [9] [10] [14] [54] [57]
α -Syn/AFFITOPE PD01A	α -syn C-terminus mimotope	KLH	Alum	Clinical	[14] [73] [74] [75] [76] [77]
α -Syn/AFFITOPE PD03A	α -syn C-terminus mimotope	KLH	Alum	Clinical	[14] [73] [74] [75] [76]
A β	A β (1-6)	BLPs ⁸ fused with peptidoglycan anchoring domain (PA)	-	Preclinical	[41]
A β	A β (1-6)	Norovirus P Particles	CpG ⁵	Preclinical	[40]
A β	A β (3-10)	KLH	CFA/IFA	Preclinical	[37] [38] [39]

Target/Vaccine	Peptide Epitope	Carrier Protein/Delivery System	Adjuvant	Type of Study	Reference
A β	A β (1-11)	Bacterial protein domain E2	Alum	Preclinical	[47]
A β /AV-1959D DNA vaccine	A β (1-11)	MultiTEP ⁹	-	Preclinical	[46]
A β /Y-5A15	A β (1-15)	Yeast cells (EBY-100)		Preclinical	[44]
A β	A β (1-15)	Silkworm pupae	Cholera toxin B subunit	Preclinical	[43]
A β	A β (1-6), A β (1-15)	Multiple antigenic peptide system	CFA/IFA ¹⁰	Preclinical	[42]
A β	cyclo[A β (22-28)-Y ¹¹ NGK'], cyclo[A β (23-29)-YNGK'], cyclo[A β (22-29)-YNGK']	Tetanus toxoid	Alum+MLPA	Preclinical	[48]
A β /AOE1	Oligomer-specific A β mimotope peptide	Yeast cell (EBY-100)	-	Preclinical	[52]
A β	A β (1-42)		CFA+bvPLA2 ₁₂	Preclinical	[50]
A β /DNA vaccine	A β (1-42)	Gold particles	-	Preclinical	[51]
A β , Tau	A β (1-11), Tau(2-18)	MultiTEP	Advax ¹³ +CpG	Preclinical	[45]
A β , Tau	Linear A β (1-6), A β (1-6)3, A β (1-15), Tau(294-305), p ⁷ Tau(396-404), pTau422, cycloA β (1-7), cycloEP1 ¹⁴ , cycloEP2 ¹⁴	HBc-VLPs conjugated with peptides via SpyCatcher/SpyTag technology ¹⁵	Alum	Preclinical	[49]
Tau	Tau(2-18)	MultiTEP	Advax+CpG	Preclinical	[61][63]
Tau	Tau(294-305)	HBc-VLPs ¹⁶	Alum	Preclinical	[64]
Tau	Tau(175-190)[p181]	Q β -VLPs		Preclinical	[66]
Tau	Tau(195-213)[p202/205], Tau(207-	-	CFA+pertussis toxin	Preclinical	[65]

Target/Vaccine	Peptide Epitope	Carrier Protein/Delivery System	Adjuvant	Type of Study	Reference
	220) [p212/214], Tau(224-238) [p231]				
Tau	Tau(379-408) [p396/404]		Alum	Preclinical	[69]
Tau	pTau30 [p202/205/238/262], pTau31 [p202/205/396/404] pTau35 [p238/262/396/404]	Norovirus P particles	CpG+AS01	Preclinical	[67]
α -Syn	α -Syn(85-99) α -Syn(109-126) α -Syn(126-140)	Tetanus toxoid	Quil A	Preclinical	[81]
α -Syn	middle region: C ¹¹ GGKNEEGAPQ (PD1) N-terminal: MDVFMKGLGGC (PD2) C-terminal: CGGEGYQDYPEA (PD3)	Q β -VLPs	-	Preclinical	[80]

disease. Nature 2016, 537, 50-56, doi:10.1038/nature19323.

6. Tolar, M.; Abushakra, S.; Hey, J.A.; Porsteinsson, A.; Sabbagh, M. Aducanumab, gantenerumab, BAN2401, and ALZ-801: the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. *Alzheimer's research & therapy* 2020, 12, 95.

¹ Q β -VLP: Virus-like particles from capsid proteins of Q β bacteriophage. ² GRM197: Nontoxic mutant of diphtheria toxin. ³ UBIT: Two different helper T cell peptide epitopes, MVF-P1H and HBSAg. ⁴ CpG: Cytosine phosphoguanosine motif. ⁵ MLPA: Monophosphoryl lipid A. ⁶ KLH: Keyhole limpet hemocyanin. ⁷ p: Phosphorylated amino acid residue(s) at a specific site in the protein sequence. ⁸ BLPs: Bacterium-like particles. ⁹ 7. Knopman, D.S.; Jones, D.T.; Greicius, M.D. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. *Alzheimer's & dementia : the journal of the Alzheimer's Association* 2021, 17, 696-701, doi:10.1002/alz.12213.

¹⁰ MultiTAP: A platform composed of 12 foreign helper T (Th) cell epitopes. ¹¹ CEA/IFA: Complete Freund's Adjuvant/incomplete Freund's Adjuvant. ¹² Amino acids shown with the one-letter code. ¹³ Advax: A novel polysaccharide-based adjuvant derived from crystalline particles of delta inulin, a natural plant sugar comprised of fructose and glucose units. ¹⁴ EP1, EP2: Special peptide epitopes of A β oligomers selected with phage display from random peptide libraries. ¹⁵ SpyCatcher/SpyTag technology: A novel disease vaccine. ¹⁶ HBMVLP: Bacteriophage-like particles. ¹⁷ BSL: Biosafety level. ¹⁸ BSL-2: Biosafety level 2. ¹⁹ BSL-3: Biosafety level 3. ²⁰ BSL-4: Biosafety level 4. ²¹ BSL-5: Biosafety level 5. ²² BSL-6: Biosafety level 6. ²³ BSL-7: Biosafety level 7. ²⁴ BSL-8: Biosafety level 8. ²⁵ BSL-9: Biosafety level 9. ²⁶ BSL-10: Biosafety level 10. ²⁷ BSL-11: Biosafety level 11. ²⁸ BSL-12: Biosafety level 12. ²⁹ BSL-13: Biosafety level 13. ³⁰ BSL-14: Biosafety level 14. ³¹ BSL-15: Biosafety level 15. ³² BSL-16: Biosafety level 16. ³³ BSL-17: Biosafety level 17. ³⁴ BSL-18: Biosafety level 18. ³⁵ BSL-19: Biosafety level 19. ³⁶ BSL-20: Biosafety level 20. ³⁷ BSL-21: Biosafety level 21. ³⁸ BSL-22: Biosafety level 22. ³⁹ BSL-23: Biosafety level 23. ⁴⁰ BSL-24: Biosafety level 24. ⁴¹ BSL-25: Biosafety level 25. ⁴² BSL-26: Biosafety level 26. ⁴³ BSL-27: Biosafety level 27. ⁴⁴ BSL-28: Biosafety level 28. ⁴⁵ BSL-29: Biosafety level 29. ⁴⁶ BSL-30: Biosafety level 30. ⁴⁷ BSL-31: Biosafety level 31. ⁴⁸ BSL-32: Biosafety level 32. ⁴⁹ BSL-33: Biosafety level 33. ⁵⁰ BSL-34: Biosafety level 34. ⁵¹ BSL-35: Biosafety level 35. ⁵² BSL-36: Biosafety level 36. ⁵³ BSL-37: Biosafety level 37. ⁵⁴ BSL-38: Biosafety level 38. ⁵⁵ BSL-39: Biosafety level 39. ⁵⁶ BSL-40: Biosafety level 40. ⁵⁷ BSL-41: Biosafety level 41. ⁵⁸ BSL-42: Biosafety level 42. ⁵⁹ BSL-43: Biosafety level 43. ⁶⁰ BSL-44: Biosafety level 44. ⁶¹ BSL-45: Biosafety level 45. ⁶² BSL-46: Biosafety level 46. ⁶³ BSL-47: Biosafety level 47. ⁶⁴ BSL-48: Biosafety level 48. ⁶⁵ BSL-49: Biosafety level 49. ⁶⁶ BSL-50: Biosafety level 50. ⁶⁷ BSL-51: Biosafety level 51. ⁶⁸ BSL-52: Biosafety level 52. ⁶⁹ BSL-53: Biosafety level 53. ⁷⁰ BSL-54: Biosafety level 54. ⁷¹ BSL-55: Biosafety level 55. ⁷² BSL-56: Biosafety level 56. ⁷³ BSL-57: Biosafety level 57. ⁷⁴ BSL-58: Biosafety level 58. ⁷⁵ BSL-59: Biosafety level 59. ⁷⁶ BSL-60: Biosafety level 60. ⁷⁷ BSL-61: Biosafety level 61. ⁷⁸ BSL-62: Biosafety level 62. ⁷⁹ BSL-63: Biosafety level 63. ⁸⁰ BSL-64: Biosafety level 64. ⁸¹ BSL-65: Biosafety level 65. ⁸² BSL-66: Biosafety level 66. ⁸³ BSL-67: Biosafety level 67. ⁸⁴ BSL-68: Biosafety level 68. ⁸⁵ BSL-69: Biosafety level 69. ⁸⁶ BSL-70: Biosafety level 70. ⁸⁷ BSL-71: Biosafety level 71. ⁸⁸ BSL-72: Biosafety level 72. ⁸⁹ BSL-73: Biosafety level 73. ⁹⁰ BSL-74: Biosafety level 74. ⁹¹ BSL-75: Biosafety level 75. ⁹² BSL-76: Biosafety level 76. ⁹³ BSL-77: Biosafety level 77. ⁹⁴ BSL-78: Biosafety level 78. ⁹⁵ BSL-79: Biosafety level 79. ⁹⁶ BSL-80: Biosafety level 80. ⁹⁷ BSL-81: Biosafety level 81. ⁹⁸ BSL-82: Biosafety level 82. ⁹⁹ BSL-83: Biosafety level 83. ¹⁰⁰ BSL-84: Biosafety level 84. ¹⁰¹ BSL-85: Biosafety level 85. ¹⁰² BSL-86: Biosafety level 86. ¹⁰³ BSL-87: Biosafety level 87. ¹⁰⁴ BSL-88: Biosafety level 88. ¹⁰⁵ BSL-89: Biosafety level 89. ¹⁰⁶ BSL-90: Biosafety level 90. ¹⁰⁷ BSL-91: Biosafety level 91. ¹⁰⁸ BSL-92: Biosafety level 92. ¹⁰⁹ BSL-93: Biosafety level 93. ¹¹⁰ BSL-94: Biosafety level 94. ¹¹¹ BSL-95: Biosafety level 95. ¹¹² BSL-96: Biosafety level 96. ¹¹³ BSL-97: Biosafety level 97. ¹¹⁴ BSL-98: Biosafety level 98. ¹¹⁵ BSL-99: Biosafety level 99. ¹¹⁶ BSL-100: Biosafety level 100. ¹¹⁷ BSL-101: Biosafety level 101. ¹¹⁸ BSL-102: Biosafety level 102. ¹¹⁹ BSL-103: Biosafety level 103. ¹²⁰ BSL-104: Biosafety level 104. ¹²¹ BSL-105: Biosafety level 105. ¹²² BSL-106: Biosafety level 106. ¹²³ BSL-107: Biosafety level 107. ¹²⁴ BSL-108: Biosafety level 108. ¹²⁵ BSL-109: Biosafety level 109. ¹²⁶ BSL-110: Biosafety level 110. ¹²⁷ BSL-111: Biosafety level 111. ¹²⁸ BSL-112: Biosafety level 112. ¹²⁹ BSL-113: Biosafety level 113. ¹³⁰ BSL-114: Biosafety level 114. ¹³¹ BSL-115: Biosafety level 115. ¹³² BSL-116: Biosafety level 116. ¹³³ BSL-117: Biosafety level 117. ¹³⁴ BSL-118: Biosafety level 118. ¹³⁵ BSL-119: Biosafety level 119. ¹³⁶ BSL-120: Biosafety level 120. ¹³⁷ BSL-121: Biosafety level 121. ¹³⁸ BSL-122: Biosafety level 122. ¹³⁹ BSL-123: Biosafety level 123. ¹⁴⁰ BSL-124: Biosafety level 124. ¹⁴¹ BSL-125: Biosafety level 125. ¹⁴² BSL-126: Biosafety level 126. ¹⁴³ BSL-127: Biosafety level 127. ¹⁴⁴ BSL-128: Biosafety level 128. ¹⁴⁵ BSL-129: Biosafety level 129. ¹⁴⁶ BSL-130: Biosafety level 130. ¹⁴⁷ BSL-131: Biosafety level 131. ¹⁴⁸ BSL-132: Biosafety level 132. ¹⁴⁹ BSL-133: Biosafety level 133. ¹⁵⁰ BSL-134: Biosafety level 134. ¹⁵¹ BSL-135: Biosafety level 135. ¹⁵² BSL-136: Biosafety level 136. ¹⁵³ BSL-137: Biosafety level 137. ¹⁵⁴ BSL-138: Biosafety level 138. ¹⁵⁵ BSL-139: Biosafety level 139. ¹⁵⁶ BSL-140: Biosafety level 140. ¹⁵⁷ BSL-141: Biosafety level 141. ¹⁵⁸ BSL-142: Biosafety level 142. ¹⁵⁹ BSL-143: Biosafety level 143. ¹⁶⁰ BSL-144: Biosafety level 144. ¹⁶¹ BSL-145: Biosafety level 145. ¹⁶² BSL-146: Biosafety level 146. ¹⁶³ BSL-147: Biosafety level 147. ¹⁶⁴ BSL-148: Biosafety level 148. ¹⁶⁵ BSL-149: Biosafety level 149. ¹⁶⁶ BSL-150: Biosafety level 150. ¹⁶⁷ BSL-151: Biosafety level 151. ¹⁶⁸ BSL-152: Biosafety level 152. ¹⁶⁹ BSL-153: Biosafety level 153. ¹⁷⁰ BSL-154: Biosafety level 154. ¹⁷¹ BSL-155: Biosafety level 155. ¹⁷² BSL-156: Biosafety level 156. ¹⁷³ BSL-157: Biosafety level 157. ¹⁷⁴ BSL-158: Biosafety level 158. ¹⁷⁵ BSL-159: Biosafety level 159. ¹⁷⁶ BSL-160: Biosafety level 160. ¹⁷⁷ BSL-161: Biosafety level 161. ¹⁷⁸ BSL-162: Biosafety level 162. ¹⁷⁹ BSL-163: Biosafety level 163. ¹⁸⁰ BSL-164: Biosafety level 164. ¹⁸¹ BSL-165: Biosafety level 165. ¹⁸² BSL-166: Biosafety level 166. ¹⁸³ BSL-167: Biosafety level 167. ¹⁸⁴ BSL-168: Biosafety level 168. ¹⁸⁵ BSL-169: Biosafety level 169. ¹⁸⁶ BSL-170: Biosafety level 170. ¹⁸⁷ BSL-171: Biosafety level 171. ¹⁸⁸ BSL-172: Biosafety level 172. ¹⁸⁹ BSL-173: Biosafety level 173. ¹⁹⁰ BSL-174: Biosafety level 174. ¹⁹¹ BSL-175: Biosafety level 175. ¹⁹² BSL-176: Biosafety level 176. ¹⁹³ BSL-177: Biosafety level 177. ¹⁹⁴ BSL-178: Biosafety level 178. ¹⁹⁵ BSL-179: Biosafety level 179. ¹⁹⁶ BSL-180: Biosafety level 180. ¹⁹⁷ BSL-181: Biosafety level 181. ¹⁹⁸ BSL-182: Biosafety level 182. ¹⁹⁹ BSL-183: Biosafety level 183. ²⁰⁰ BSL-184: Biosafety level 184. ²⁰¹ BSL-185: Biosafety level 185. ²⁰² BSL-186: Biosafety level 186. ²⁰³ BSL-187: Biosafety level 187. ²⁰⁴ BSL-188: Biosafety level 188. ²⁰⁵ BSL-189: Biosafety level 189. ²⁰⁶ BSL-190: Biosafety level 190. ²⁰⁷ BSL-191: Biosafety level 191. ²⁰⁸ BSL-192: Biosafety level 192. ²⁰⁹ BSL-193: Biosafety level 193. ²¹⁰ BSL-194: Biosafety level 194. ²¹¹ BSL-195: Biosafety level 195. ²¹² BSL-196: Biosafety level 196. ²¹³ BSL-197: Biosafety level 197. ²¹⁴ BSL-198: Biosafety level 198. ²¹⁵ BSL-199: Biosafety level 199. ²¹⁶ BSL-200: Biosafety level 200. ²¹⁷ BSL-201: Biosafety level 201. ²¹⁸ BSL-202: Biosafety level 202. ²¹⁹ BSL-203: Biosafety level 203. ²²⁰ BSL-204: Biosafety level 204. ²²¹ BSL-205: Biosafety level 205. ²²² BSL-206: Biosafety level 206. ²²³ BSL-207: Biosafety level 207. ²²⁴ BSL-208: Biosafety level 208. ²²⁵ BSL-209: Biosafety level 209. ²²⁶ BSL-210: Biosafety level 210. ²²⁷ BSL-211: Biosafety level 211. ²²⁸ BSL-212: Biosafety level 212. ²²⁹ BSL-213: Biosafety level 213. ²³⁰ BSL-214: Biosafety level 214. ²³¹ BSL-215: Biosafety level 215. ²³² BSL-216: Biosafety level 216. ²³³ BSL-217: Biosafety level 217. ²³⁴ BSL-218: Biosafety level 218. ²³⁵ BSL-219: Biosafety level 219. ²³⁶ BSL-220: Biosafety level 220. ²³⁷ BSL-221: Biosafety level 221. ²³⁸ BSL-222: Biosafety level 222. ²³⁹ BSL-223: Biosafety level 223. ²⁴⁰ BSL-224: Biosafety level 224. ²⁴¹ BSL-225: Biosafety level 225. ²⁴² BSL-226: Biosafety level 226. ²⁴³ BSL-227: Biosafety level 227. ²⁴⁴ BSL-228: Biosafety level 228. ²⁴⁵ BSL-229: Biosafety level 229. ²⁴⁶ BSL-230: Biosafety level 230. ²⁴⁷ BSL-231: Biosafety level 231. ²⁴⁸ BSL-232: Biosafety level 232. ²⁴⁹ BSL-233: Biosafety level 233. ²⁵⁰ BSL-234: Biosafety level 234. ²⁵¹ BSL-235: Biosafety level 235. ²⁵² BSL-236: Biosafety level 236. ²⁵³ BSL-237: Biosafety level 237. ²⁵⁴ BSL-238: Biosafety level 238. ²⁵⁵ BSL-239: Biosafety level 239. ²⁵⁶ BSL-240: Biosafety level 240. ²⁵⁷ BSL-241: Biosafety level 241. ²⁵⁸ BSL-242: Biosafety level 242. ²⁵⁹ BSL-243: Biosafety level 243. ²⁶⁰ BSL-244: Biosafety level 244. ²⁶¹ BSL-245: Biosafety level 245. ²⁶² BSL-246: Biosafety level 246. ²⁶³ BSL-247: Biosafety level 247. ²⁶⁴ BSL-248: Biosafety level 248. ²⁶⁵ BSL-249: Biosafety level 249. ²⁶⁶ BSL-250: Biosafety level 250. ²⁶⁷ BSL-251: Biosafety level 251. ²⁶⁸ BSL-252: Biosafety level 252. ²⁶⁹ BSL-253: Biosafety level 253. ²⁷⁰ BSL-254: Biosafety level 254. ²⁷¹ BSL-255: Biosafety level 255. ²⁷² BSL-256: Biosafety level 256. ²⁷³ BSL-257: Biosafety level 257. ²⁷⁴ BSL-258: Biosafety level 258. ²⁷⁵ BSL-259: Biosafety level 259. ²⁷⁶ BSL-260: Biosafety level 260. ²⁷⁷ BSL-261: Biosafety level 261. ²⁷⁸ BSL-262: Biosafety level 262. ²⁷⁹ BSL-263: Biosafety level 263. ²⁸⁰ BSL-264: Biosafety level 264. ²⁸¹ BSL-265: Biosafety level 265. ²⁸² BSL-266: Biosafety level 266. ²⁸³ BSL-267: Biosafety level 267. ²⁸⁴ BSL-268: Biosafety level 268. ²⁸⁵ BSL-269: Biosafety level 269. ²⁸⁶ BSL-270: Biosafety level 270. ²⁸⁷ BSL-271: Biosafety level 271. ²⁸⁸ BSL-272: Biosafety level 272. ²⁸⁹ BSL-273: Biosafety level 273. ²⁹⁰ BSL-274: Biosafety level 274. ²⁹¹ BSL-275: Biosafety level 275. ²⁹² BSL-276: Biosafety level 276. ²⁹³ BSL-277: Biosafety level 277. ²⁹⁴ BSL-278: Biosafety level 278. ²⁹⁵ BSL-279: Biosafety level 279. ²⁹⁶ BSL-280: Biosafety level 280. ²⁹⁷ BSL-281: Biosafety level 281. ²⁹⁸ BSL-282: Biosafety level 282. ²⁹⁹ BSL-283: Biosafety level 283. ³⁰⁰ BSL-284: Biosafety level 284. ³⁰¹ BSL-285: Biosafety level 285. ³⁰² BSL-286: Biosafety level 286. ³⁰³ BSL-287: Biosafety level 287. ³⁰⁴ BSL-288: Biosafety level 288. ³⁰⁵ BSL-289: Biosafety level 289. ³⁰⁶ BSL-290: Biosafety level 290. ³⁰⁷ BSL-291: Biosafety level 291. ³⁰⁸ BSL-292: Biosafety level 292. ³⁰⁹ BSL-293: Biosafety level 293. ³¹⁰ BSL-294: Biosafety level 294. ³¹¹ BSL-295: Biosafety level 295. ³¹² BSL-296: Biosafety level 296. ³¹³ BSL-297: Biosafety level 297. ³¹⁴ BSL-298: Biosafety level 298. ³¹⁵ BSL-299: Biosafety level 299. ³¹⁶ BSL-300: Biosafety level 300. ³¹⁷ BSL-301: Biosafety level 301. ³¹⁸ BSL-302: Biosafety level 302. ³¹⁹ BSL-303: Biosafety level 303. ³²⁰ BSL-304: Biosafety level 304. ³²¹ BSL-305: Biosafety level 305. ³²² BSL-306: Biosafety level 306. ³²³ BSL-307: Biosafety level 307. ³²⁴ BSL-308: Biosafety level 308. ³²⁵ BSL-309: Biosafety level 309. ³²⁶ BSL-310: Biosafety level 310. ³²⁷ BSL-311: Biosafety level 311. ³²⁸ BSL-312: Biosafety level 312. ³²⁹ BSL-313: Biosafety level 313. ³³⁰ BSL-314: Biosafety level 314. ³³¹ BSL-315: Biosafety level 315. ³³² BSL-316: Biosafety level 316. ³³³ BSL-317: Biosafety level 317. ³³⁴ BSL-318: Biosafety level 318. ³³⁵ BSL-319: Biosafety level 319. ³³⁶ BSL-320: Biosafety level 320. ³³⁷ BSL-321: Biosafety level 321. ³³⁸ BSL-322: Biosafety level 322. ³³⁹ BSL-323: Biosafety level 323. ³⁴⁰ BSL-324: Biosafety level 324. ³⁴¹ BSL-325: Biosafety level 325. ³⁴² BSL-326: Biosafety level 326. ³⁴³ BSL-327: Biosafety level 327. ³⁴⁴ BSL-328: Biosafety level 328. ³⁴⁵ BSL-329: Biosafety level 329. ³⁴⁶ BSL-330: Biosafety level 330. ³⁴⁷ BSL-331: Biosafety level 331. ³⁴⁸ BSL-332: Biosafety level 332. ³⁴⁹ BSL-333: Biosafety level 333. ³⁵⁰ BSL-334: Biosafety level 334. ³⁵¹ BSL-335: Biosafety level 335. ³⁵² BSL-336: Biosafety level 336. ³⁵³ BSL-337: Biosafety level 337. ³⁵⁴ BSL-338: Biosafety level 338. ³⁵⁵ BSL-339: Biosafety level 339. ³⁵⁶ BSL-340: Biosafety level 340. ³⁵⁷ BSL-341: Biosafety level 341. ³⁵⁸ BSL-342: Biosafety level 342. ³⁵⁹ BSL-343: Biosafety level 343. ³⁶⁰ BSL-344: Biosafety level 344. ³⁶¹ BSL-345: Biosafety level 345. ³⁶² BSL-346: Biosafety level 346. ³⁶³ BSL-347: Biosafety level 347. ³⁶⁴ BSL-348: Biosafety level 348. ³⁶⁵ BSL-349: Biosafety level 349. ³⁶⁶ BSL-350: Biosafety level 350. ³⁶⁷ BSL-351: Biosafety level 351. ³⁶⁸ BSL-352: Biosafety level 352. ³⁶⁹ BSL-353: Biosafety level 353. ³⁷⁰ BSL-354: Biosafety level 354. ³⁷¹ BSL-355: Biosafety level 355. ³⁷² BSL-356: Biosafety level 356. ³⁷³ BSL-357: Biosafety level 357. ³⁷⁴ BSL-358: Biosafety level 358. ³⁷⁵ BSL-359: Biosafety level 359. ³⁷⁶ BSL-360: Biosafety level 360. ³⁷⁷ BSL-361: Biosafety level 361. ³⁷⁸ BSL-362: Biosafety level 362. ³⁷⁹ BSL-363: Biosafety level 363. ³⁸⁰ BSL-364: Biosafety level 364. ³⁸¹ BSL-365: Biosafety level 365. ³⁸² BSL-366: Biosafety level 366. ³⁸³ BSL-367: Biosafety level 367. ³⁸⁴ BSL-368: Biosafety level 368. ³⁸⁵ BSL-369: Biosafety level 369. ³⁸⁶ BSL-370: Biosafety level 370. ³⁸⁷ BSL-371: Biosafety level 371. ³⁸⁸ BSL-372: Biosafety level 372. ³⁸⁹ BSL-373: Biosafety level 373. ³⁹⁰ BSL-374: Biosafety level 374. ³⁹¹ BSL-375: Biosafety level 375. ³⁹² BSL-376: Biosafety level 376. ³⁹³ BSL-377: Biosafety level 377. ³⁹⁴ BSL-378: Biosafety level 378. ³⁹⁵ BSL-379: Biosafety level 379. ³⁹⁶ BSL-380: Biosafety level 380. ³⁹⁷ BSL-381: Biosafety level 381. ³⁹⁸ BSL-382: Biosafety level 382. ³⁹⁹ BSL-383: Biosafety level 383. ⁴⁰⁰ BSL-384: Biosafety level 384. ⁴⁰¹ BSL-385: Biosafety level 385. ⁴⁰² BSL-386: Biosafety level 386. ⁴⁰³ BSL-387: Biosafety level 387. ⁴⁰⁴ BSL-388: Biosafety level 388. ⁴⁰⁵ BSL-389: Biosafety level 389. ⁴⁰⁶ BSL-390: Biosafety level 390. ⁴⁰⁷ BSL-391: Biosafety level 391. ⁴⁰⁸ BSL-392: Biosafety level 392. ⁴⁰⁹ BSL-393: Biosafety level 393. ⁴¹⁰ BSL-394: Biosafety level 394. ⁴¹¹ BSL-395: Biosafety level 395. ⁴¹² BSL-396: Biosafety level 396. ⁴¹³ BSL-397: Biosafety level 397. ⁴¹⁴ BSL-398: Biosafety level 398. ⁴¹⁵ BSL-399: Biosafety level 399. ⁴¹⁶ BSL-400: Biosafety level 400. ⁴¹⁷ BSL-401: Biosafety level 401. ⁴¹⁸ BSL-402: Biosafety level 402. ⁴¹⁹ BSL-403: Biosafety level 403. ⁴²⁰ BSL-404: Biosafety level 404. ⁴²¹ BSL-405: Biosafety level 405. ⁴²² BSL-406: Biosafety level 406. ⁴²³ BSL-407: Biosafety level 407. ⁴²⁴ BSL-408: Biosafety level 408. ⁴²⁵ BSL-409: Biosafety level 409. ⁴²⁶ BSL-410: Biosafety level 410. ⁴²⁷ BSL-411: Biosafety level 411. ⁴²⁸ BSL-412: Biosafety level 412. ⁴²⁹ BSL-413: Biosafety level 413. ⁴³⁰ BSL-414: Biosafety level 414. ⁴³¹ BSL-415: Biosafety level 415. ⁴³² BSL-416: Biosafety level 416. ⁴³³ BSL-417: Biosafety level 417. ⁴³⁴ BSL-418: Biosafety level 418. ⁴³⁵ BSL-419: Biosafety level 419. ⁴³⁶ BSL-420: Biosafety level 420. ⁴³⁷ BSL-421: Biosafety level 421. ⁴³⁸ BSL-422: Biosafety level 422. ⁴³⁹ BSL-423: Biosafety level 423. ⁴⁴⁰ BSL-424: Biosafety level 424. ⁴⁴¹ BSL-425: Biosafety level 425. ⁴⁴² BSL-426: Biosafety level 426. ⁴⁴³ BSL-427: Biosafety level 427. ⁴⁴⁴ BSL-428: Biosafety level 428. ⁴⁴⁵ BSL-429: Biosafety level 429. ⁴⁴⁶ BSL-430: Biosafety level 430. ⁴⁴⁷ BSL-431: Biosafety level 431. ⁴⁴⁸ BSL-432: Biosafety level 432. ⁴⁴⁹ BSL-433: Biosafety level 433. ⁴⁵⁰ BSL-434: Biosafety level 434. ⁴⁵¹ BSL-435: Biosafety level 435. ⁴⁵² BSL-436: Biosafety level 436. ⁴⁵³ BSL-437: Biosafety level 437. ⁴⁵⁴ BSL-438: Biosafety level 438. ⁴⁵⁵ BSL-439: Biosafety level 439. ⁴⁵⁶ BSL-440: Biosafety level 440. ⁴⁵⁷ BSL-441: Biosafety level 441. ⁴⁵⁸ BSL-442: Biosafety level 442. ⁴⁵⁹ BSL-443: Biosafety level 443. ⁴⁶⁰ BSL-444: Biosafety level 444. ⁴⁶¹ BSL-445: Biosafety level 445. ⁴⁶² BSL-446: Biosafety level 446. ⁴⁶³ BSL-447: Biosafety level 447. ⁴⁶⁴ BSL-448: Biosafety level 448. ⁴⁶⁵ BSL-449: Biosafety level 449. ⁴⁶⁶ BSL-450: Biosafety level 450. ⁴⁶⁷ BSL-451: Biosafety level 451. ⁴⁶⁸ BSL-452: Biosafety level 452. ⁴⁶⁹ BSL-453: Biosafety level 453. ⁴⁷⁰ BSL-454: Biosafety level 454. ⁴⁷¹ BSL-455: Biosafety level 455. ⁴⁷² BSL-456: Biosafety level 456. ⁴⁷³ BSL-457: Biosafety level 457. ⁴⁷⁴ BSL-458: Biosafety level 458. ⁴⁷⁵ BSL-459: Biosafety level 459. ⁴⁷⁶ BSL-460: Biosafety level 460. ⁴⁷⁷ BSL-461: Biosafety level 461. ⁴⁷⁸ BSL-462: Biosafety level 462. ⁴⁷⁹ BSL-463: Biosafety level 463. ⁴⁸⁰ BSL-464: Biosafety level 464. ⁴⁸¹ BSL-465: Biosafety level 465. ⁴⁸² BSL-466: Biosafety level 466. ⁴⁸³ BSL-467: Biosafety level 467. ⁴⁸⁴ BSL-468: Biosafety level 468. ⁴⁸⁵ BSL-469: Biosafety level 469. ⁴⁸⁶ BSL-470: Biosafety level 470. ⁴⁸⁷ BSL-471: Biosafety level 471. ⁴⁸⁸ BSL-472: Biosafety level 472. ⁴⁸⁹ BSL-473

- Perspectives. *Molecules* 2021, 26, 430, doi:10.3390/molecules26020430.
12. Valera, E.; Spencer, B.; Masliah, E. Immunotherapeutic Approaches Targeting Amyloid- β , α -Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics* 2016, 13, 179-189, doi:10.1007/s13311-015-0397-z.
 13. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.L.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. *Nature medicine* 2000, 6, 916-919, doi:10.1038/78682.
 14. Kwon, S.; Iba, M.; Kim, C.; Masliah, E. Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics* 2020, 17, 935-954, doi:10.1007/s13311-020-00853-2.
 15. Freir, D.B.; Nicoll, A.J.; Klyubin, I.; Panico, S.; Mc Donald, J.M.; Risse, E.; Asante, E.A.; Farrow, M.A.; Sessions, R.B.; Saibil, H.R.; et al. Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. *Nature communications* 2011, 2, 336, doi:10.1038/ncomms1341.
 16. Corbett, G.T.; Wang, Z.; Hong, W.; Colom-Cadena, M.; Rose, J.; Liao, M.; Asfaw, A.; Hall, T.C.; Ding, L.; DeSousa, A.; et al. PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. *Acta neuropathologica* 2020, 139, 503-526, doi:10.1007/s00401-019-02114-9.
 17. Boutajangout, A.; Zhang, W.; Kim, J.; Abdali, W.A.; Prelli, F.; Wisniewski, T. Passive Immunization With a Novel Monoclonal Anti-PrP Antibody TW1 in an Alzheimer's Mouse Model With Tau Pathology. *Frontiers in aging neuroscience* 2021, 13, 640677, doi:10.3389/fnagi.2021.640677.
 18. Wells, C.; Brennan, S.; Keon, M.; Ooi, L. The role of amyloid oligomers in neurodegenerative pathologies. *International journal of biological macromolecules* 2021, 181, 582-604, doi:10.1016/j.ijbiomac.2021.03.113.
 19. Zhou, Q.; Mareljic, N.; Michaelsen, M.; Parhizkar, S.; Heindl, S.; Nuscher, B.; Farny, D.; Czuppa, M.; Schludi, C.; Graf, A.; et al. Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model. *EMBO molecular medicine* 2020, 12, e10919, doi:10.15252/emmm.201910919.
 20. Ramsingh, A.I.; Manley, K.; Rong, Y.; Reilly, A.; Messer, A. Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's disease. *Human molecular genetics* 2015, 24, 6186-6197, doi:10.1093/hmg/ddv335.

21. Skwarczynski, M.; Toth, I. Peptide-based synthetic vaccines. *Chemical science* 2016, 7, 842-854, doi:10.1039/c5sc03892h.
22. Sanchez-Trincado, J.L.; Gomez-Perosanz, M.; Reche, P.A. Fundamentals and Methods for T- and B-Cell Epitope Prediction. *Journal of immunology research* 2017, 2017, 2680160, doi:10.1155/2017/2680160.
23. Fleri, W.; Paul, S.; Dhanda, S.K.; Mahajan, S.; Xu, X.; Peters, B.; Sette, A. The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design. *Frontiers in immunology* 2017, 8, 278, doi:10.3389/fimmu.2017.00278.
24. Raoufi, E.; Hemmati, M.; Eftekhari, S.; Khaksaran, K.; Mahmodi, Z.; Farajollahi, M.M.; Mohsenzadegan, M. Epitope Prediction by Novel Immunoinformatics Approach: A State-of-the-art Review. *International journal of peptide research and therapeutics* 2020, 26, 1155-1163, doi:10.1007/s10989-019-09918-z.
25. Schenk, D.; Barbour, R.; Dunn, W.; Gordon, G.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature* 1999, 400, 173-177, doi:10.1038/22124.
26. Nicoll, J.A.R.; Buckland, G.R.; Harrison, C.H.; Page, A.; Harris, S.; Love, S.; Neal, J.W.; Holmes, C.; Boche, D. Persistent neuropathological effects 14 years following amyloid- β immunization in Alzheimer's disease. *Brain : a journal of neurology* 2019, 142, 2113-2126, doi:10.1093/brain/awz142.
27. Wisniewski, T.; Goñi, F. Immunotherapeutic approaches for Alzheimer's disease. *Neuron* 2015, 85, 1162-1176, doi:10.1016/j.neuron.2014.12.064.
28. Marciani, D.J. Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine. *Research (Washington, D.C.)* 2019, 2019, 5341375, doi:10.34133/2019/5341375.
29. Mo, J.J.; Li, J.Y.; Yang, Z.; Liu, Z.; Feng, J.S. Efficacy and safety of anti-amyloid- β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis. *Annals of clinical and translational neurology* 2017, 4, 931-942, doi:10.1002/acn3.469.
30. Farlow, M.R.; Andreasen, N.; Riviere, M.E.; Vostiar, I.; Vitaliti, A.; Sovago, J.; Caputo, A.; Winblad, B.; Graf, A. Long-term treatment with active A β immunotherapy with CAD106 in mild Alzheimer's disease. *Alzheimer's research & therapy* 2015, 7, 23, doi:10.1186/s13195-015-0108-3.
31. Vandenberghe, R.; Riviere, M.E.; Caputo, A.; Sovago, J.; Maguire, R.P.; Farlow, M.; Marotta, G.; Sanchez-Valle, R.; Scheltens, P.; Ryan, J.M.; et al. Active A β immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. *Alzheimer's & dementia (New York, N. Y.)* 2017, 3, 10-22, doi:10.1016/j.trci.2016.12.003.

32. Pasquier, F.; Sadowsky, C.; Holstein, A.; Leterme Gle, P.; Peng, Y.; Jackson, N.; Fox, N.C.; Ketter, N.; Liu, E.; Ryan, J.M. Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. *Journal of Alzheimer's disease* : JAD 2016, 51, 1131-1143, doi:10.3233/jad-150376.
33. Wang, C.Y.; Wang, P.N.; Chiu, M.J.; Finstad, C.L.; Lin, F.; Lynn, S.; Tai, Y.H.; De Fang, X.; Zhao, K.; Hung, C.H.; et al. UB-311, a novel UBITH® amyloid β peptide vaccine for mild Alzheimer's disease. *Alzheimer's & dementia (New York, N. Y.)* 2017, 3, 262-272, doi:10.1016/j.trci.2017.03.005.
34. Lacosta, A.M.; Pascual-Lucas, M.; Pesini, P.; Casabona, D.; Pérez-Grijalba, V.; Marcos-Campos, I.; Sarasa, L.; Canudas, J.; Badi, H.; Monleón, I.; et al. Safety, tolerability and immunogenicity of an active anti-A β (40) vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial. *Alzheimer's research & therapy* 2018, 10, 12, doi:10.1186/s13195-018-0340-8.
35. Marciani, D.J. A retrospective analysis of the Alzheimer's disease vaccine progress - The critical need for new development strategies. *Journal of neurochemistry* 2016, 137, 687-700, doi:10.1111/jnc.13608.
36. Schneeberger, A.; Hendrix, S.; Mandler, M.; Ellison, N.; Bürger, V.; Brunner, M.; Frölich, L.; Mimica, N.; Hort, J.; Rainer, M.; et al. Results from a Phase II Study to Assess the Clinical and Immunological Activity of AFFITOPE® AD02 in Patients with Early Alzheimer's Disease. *The journal of prevention of Alzheimer's disease* 2015, 2, 103-114, doi:10.14283/jpad.2015.63.
37. Wang, J.C.; Zhu, K.; Zhang, H.Y.; Wang, G.Q.; Liu, H.Y.; Cao, Y.P. Early active immunization with A β (3-10)-KLH vaccine reduces tau phosphorylation in the hippocampus and protects cognition of mice. *Neural regeneration research* 2020, 15, 519-527, doi:10.4103/1673-5374.266061.
38. Ding, L.; Meng, Y.; Zhang, H.Y.; Yin, W.C.; Yan, Y.; Cao, Y.P. Prophylactic active immunization with a novel epitope vaccine improves cognitive ability by decreasing amyloid plaques and neuroinflammation in APP/PS1 transgenic mice. *Neuroscience research* 2017, 119, 7-14, doi:10.1016/j.neures.2017.01.003.
39. Zhang, X.Y.; Meng, Y.; Yan, X.J.; Liu, S.; Wang, G.Q.; Cao, Y.P. Immunization with A β 3-10-KLH vaccine improves cognitive function and ameliorates mitochondrial dysfunction and reduces Alzheimer's disease-like pathology in Tg-APPswe/PSEN1dE9 mice. *Brain research bulletin* 2021, 174, 31-40, doi:10.1016/j.brainresbull.2021.05.019.
40. Yang, P.; Guo, Y.; Sun, Y.; Yu, B.; Zhang, H.; Wu, J.; Yu, X.; Wu, H.; Kong, W. Active immunization with norovirus P particle-based amyloid- β chimeric protein vaccine induces high titers of anti-A β antibodies in mice. *BMC immunology* 2019, 20, 9, doi:10.1186/s12865-019-0289-9.
41. Fu, L.; Guo, Y.; Sun, Y.; Dong, Y.; Wu, J.; Yu, B.; Zhang, H.; Yu, X.; Wu, H.; Kong, W. A novel A β epitope vaccine based on bacterium-like particle against Alzheimer's disease. *Molecular*

- immunology 2018, 101, 259-267, doi:10.1016/j.molimm.2018.07.019.
42. Sun, D.; Qiao, Y.; Jiang, X.; Li, P.; Kuai, Z.; Gong, X.; Liu, D.; Fu, Q.; Sun, L.; Li, H.; et al. Multiple Antigenic Peptide System Coupled with Amyloid Beta Protein Epitopes As An Immunization Approach to Treat Alzheimer's Disease. *ACS chemical neuroscience* 2019, 10, 2794-2800, doi:10.1021/acscchemneuro.9b00020.
 43. Li, S.; Jin, Y.; Wang, C.; Chen, J.; Yu, W.; Jin, Y.; Lv, Z. Effects of a 15-amino-acid isoform of amyloid- β expressed by silkworm pupae on B6C3-Tg Alzheimer's disease transgenic mice. *Journal of biotechnology* 2019, 296, 83-92, doi:10.1016/j.jbiotec.2019.03.013.
 44. Liu, D.Q.; Lu, S.; Zhang, L.; Huang, Y.R.; Ji, M.; Sun, X.Y.; Liu, X.G.; Liu, R.T. Yeast-Based A β 1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer's Disease Transgenic Mice. *Vaccines* 2020, 8, doi:10.3390/vaccines8030351.
 45. Davtyan, H.; Hovakimyan, A.; Kiani Shabestari, S.; Antonyan, T.; Coburn, M.A.; Zagorski, K.; Chailyan, G.; Petrushina, I.; Svystun, O.; Danhash, E.; et al. Testing a MultiTEP-based combination vaccine to reduce A β and tau pathology in Tau22/5xFAD bigenic mice. *Alzheimer's research & therapy* 2019, 11, 107, doi:10.1186/s13195-019-0556-2.
 46. Petrushina, I.; Hovakimyan, A.; Harahap-Carrillo, I.S.; Davtyan, H.; Antonyan, T.; Chailyan, G.; Kazarian, K.; Antonenko, M.; Jullienne, A.; Hamer, M.M.; et al. Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. *Neurobiology of disease* 2020, 139, 104823, doi:10.1016/j.nbd.2020.104823.
 47. Mantile, F.; Capasso, A.; Villacampa, N.; Donnini, M.; Liguori, G.L.; Constantin, G.; De Berardinis, P.; Heneka, M.T.; Prisco, A. Vaccination with (1-11)E2 in alum efficiently induces an antibody response to β -amyloid without affecting brain β -amyloid load and microglia activation in 3xTg mice. *Aging clinical and experimental research* 2021, 33, 1383-1387, doi:10.1007/s40520-019-01414-0.
 48. Oberman, K.; Gouweleeuw, L.; Hoogerhout, P.; Eisel, U.L.M.; van Riet, E.; Schoemaker, R.G. Vaccination Prevented Short-Term Memory Loss, but Deteriorated Long-Term Spatial Memory in Alzheimer's Disease Mice, Independent of Amyloid- β Pathology. *Journal of Alzheimer's disease reports* 2020, 4, 261-280, doi:10.3233/adr-200213.
 49. Ji, M.; Xie, X.; dong qun, L.; Lu, S.; Zhang, L.; Huang, Y.-R.; Liu, R. Engineered hepatitis B core virus-like particle carrier for precise and personalized Alzheimer's disease vaccine preparation via fixed-point coupling. *Applied Materials Today* 2020, 19, doi:10.1016/j.apmt.2020.100575.
 50. Baek, H.; Lee, C.J.; Choi, D.B.; Kim, N.S.; Kim, Y.S.; Ye, Y.J.; Kim, Y.S.; Kim, J.S.; Shim, I.; Bae, H. Bee venom phospholipase A2 ameliorates Alzheimer's disease pathology in A β vaccination treatment without inducing neuro-inflammation in a 3xTg-AD mouse model. *Scientific reports* 2018, 8, 17369, doi:10.1038/s41598-018-35030-1.

51. Rosenberg, R.N.; Fu, M.; Lambracht-Washington, D. Active full-length DNA A β (42) immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology. *Alzheimer's research & therapy* 2018, 10, 115, doi:10.1186/s13195-018-0441-4.
52. Yu, X.L.; Zhu, J.; Liu, X.M.; Xu, P.X.; Zhang, Y.; Liu, R.T. Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid- β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice. *British journal of pharmacology* 2020, 177, 2860-2871, doi:10.1111/bph.15015.
53. Hoskin, J.L.; Sabbagh, M.N.; Al-Hasan, Y.; Decourt, B. Tau immunotherapies for Alzheimer's disease. *Expert opinion on investigational drugs* 2019, 28, 545-554, doi:10.1080/13543784.2019.1619694.
54. Herline, K.; Drummond, E.; Wisniewski, T. Recent advancements toward therapeutic vaccines against Alzheimer's disease. *Expert review of vaccines* 2018, 17, 707-721, doi:10.1080/14760584.2018.1500905.
55. Shahpasand, K.; Sepehri Shamloo, A.; Nabavi, S.M.; Ping Lu, K.; Zhen Zhou, X. "Tau immunotherapy: Hopes and hindrances". *Human vaccines & immunotherapeutics* 2018, 14, 277-284, doi:10.1080/21645515.2017.1393594.
56. Novak, P.; Schmidt, R.; Kontsekova, E.; Zilka, N.; Kovacech, B.; Skrabana, R.; Vince-Kazmerova, Z.; Katina, S.; Fialova, L.; Prcina, M.; et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. *The Lancet. Neurology* 2017, 16, 123-134, doi:10.1016/s1474-4422(16)30331-3.
57. Novak, P.; Kontsekova, E.; Zilka, N.; Novak, M. Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead. *Frontiers in neuroscience* 2018, 12, 798, doi:10.3389/fnins.2018.00798.
58. Novak, P.; Schmidt, R.; Kontsekova, E.; Kovacech, B.; Smolek, T.; Katina, S.; Fialova, L.; Prcina, M.; Parrak, V.; Dal-Bianco, P.; et al. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. *Alzheimer's research & therapy* 2018, 10, 108, doi:10.1186/s13195-018-0436-1.
59. Kontsekova, E.; Zilka, N.; Kovacech, B.; Skrabana, R.; Novak, M. Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. *Alzheimer's research & therapy* 2014, 6, 45, doi:10.1186/alzrt277.
60. Kontsekova, E.; Zilka, N.; Kovacech, B.; Novak, P.; Novak, M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. *Alzheimer's research & therapy* 2014, 6, 44, doi:10.1186/alzrt278.

61. Joly-Amado, A.; Davtyan, H.; Serraneau, K.; Jules, P.; Zitnyar, A.; Pressman, E.; Zagorski, K.; Antonyan, T.; Hovakimyan, A.; Paek, H.J.; et al. Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology. *Neurobiology of disease* 2020, 134, 104636, doi:10.1016/j.nbd.2019.104636.
62. Davtyan, H.; Zagorski, K.; Rajapaksha, H.; Hovakimyan, A.; Davtyan, A.; Petrushina, I.; Kazarian, K.; Cribbs, D.H.; Petrovsky, N.; Agadjanyan, M.G.; et al. Alzheimer's disease Advax(CpG)-adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and A β pathological molecules. *Scientific reports* 2016, 6, 28912, doi:10.1038/srep28912.
63. Hovakimyan, A.; Antonyan, T.; Shabestari, S.K.; Svystun, O.; Chailyan, G.; Coburn, M.A.; Carlen-Jones, W.; Petrushina, I.; Chadarevian, J.P.; Zagorski, K.; et al. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice. *Scientific reports* 2019, 9, 15455, doi:10.1038/s41598-019-51809-2.
64. Ji, M.; Xie, X.X.; Liu, D.Q.; Yu, X.L.; Zhang, Y.; Zhang, L.X.; Wang, S.W.; Huang, Y.R.; Liu, R.T. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia. *Alzheimer's research & therapy* 2018, 10, 55, doi:10.1186/s13195-018-0378-7.
65. Benhamron, S.; Rozenstein-Tsalkovich, L.; Nitzan, K.; Abramsky, O.; Rosenmann, H. Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques. *Experimental neurology* 2018, 303, 48-58, doi:10.1016/j.expneurol.2018.02.004.
66. Maphis, N.M.; Peabody, J.; Crossey, E.; Jiang, S.; Jamaledin Ahmad, F.A.; Alvarez, M.; Mansoor, S.K.; Yaney, A.; Yang, Y.; Sillerud, L.O.; et al. Q β Virus-like particle-based vaccine induces robust immunity and protects against tauopathy. *NPJ vaccines* 2019, 4, 26, doi:10.1038/s41541-019-0118-4.
67. Sun, Y.; Guo, Y.; Feng, X.; Fu, L.; Zheng, Y.; Dong, Y.; Zhang, Y.; Yu, X.; Kong, W.; Wu, H. Norovirus P particle-based tau vaccine-generated phosphorylated tau antibodies markedly ameliorate tau pathology and improve behavioral deficits in mouse model of Alzheimer's disease. *Signal transduction and targeted therapy* 2021, 6, 61, doi:10.1038/s41392-020-00416-z.
68. Teng, I.T.; Li, X.; Yadikar, H.A.; Yang, Z.; Li, L.; Lyu, Y.; Pan, X.; Wang, K.K.; Tan, W. Identification and Characterization of DNA Aptamers Specific for Phosphorylation Epitopes of Tau Protein. *Journal of the American Chemical Society* 2018, 140, 14314-14323, doi:10.1021/jacs.8b08645.
69. Rajamohamedsait, H.; Rasool, S.; Rajamohamedsait, W.; Lin, Y.; Sigurdsson, E.M. Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid- β Pathologies in

- 3xTg Mice. *Scientific reports* 2017, 7, 17034, doi:10.1038/s41598-017-17313-1.
70. Almandoz-Gil, L.; Lindström, V.; Sigvardson, J.; Kahle, P.J.; Lannfelt, L.; Ingelsson, M.; Bergström, J. Mapping of Surface-Exposed Epitopes of In Vitro and In Vivo Aggregated Species of Alpha-Synuclein. *Cellular and molecular neurobiology* 2017, 37, 1217-1226, doi:10.1007/s10571-016-0454-0.
 71. Li, X.; Koudstaal, W.; Fletcher, L.; Costa, M.; van Winsen, M.; Siregar, B.; Inganäs, H.; Kim, J.; Keogh, E.; Macedo, J.; et al. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology. *Acta neuropathologica* 2019, 137, 825-836, doi:10.1007/s00401-019-01974-5.
 72. Mandaci, S.Y.; Caliskan, M.; Sariaslan, M.F.; Uversky, V.N.; Coskuner-Weber, O. Epitope region identification challenges of intrinsically disordered proteins in neurodegenerative diseases: Secondary structure dependence of α -synuclein on simulation techniques and force field parameters. *Chemical biology & drug design* 2020, 96, 659-667, doi:10.1111/cbdd.13662.
 73. Jamal, F. Immunotherapies Targeting α -Synuclein in Parkinson Disease. *Federal practitioner : for the health care professionals of the VA, DoD, and PHS* 2020, 37, 375-379, doi:10.12788/fp.0026.
 74. McFarthing, K.; Simuni, T. Clinical Trial Highlights: Targeting Alpha-Synuclein. *Journal of Parkinson's disease* 2019, 9, 5-16, doi:10.3233/jpd-189004.
 75. Chatterjee, D.; Kordower, J.H. Immunotherapy in Parkinson's disease: Current status and future directions. *Neurobiology of disease* 2019, 132, 104587, doi:10.1016/j.nbd.2019.104587.
 76. Meissner, W.G.; Traon, A.P.; Foubert-Samier, A.; Galabova, G.; Galitzky, M.; Kutzelnigg, A.; Laurens, B.; Lühns, P.; Medori, R.; Péran, P.; et al. A Phase 1 Randomized Trial of Specific Active α -Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. *Movement disorders : official journal of the Movement Disorder Society* 2020, 35, 1957-1965, doi:10.1002/mds.28218.
 77. Volc, D.; Poewe, W.; Kutzelnigg, A.; Lühns, P.; Thun-Hohenstein, C.; Schneeberger, A.; Galabova, G.; Majbour, N.; Vaikath, N.; El-Agnaf, O.; et al. Safety and immunogenicity of the α -synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. *The Lancet. Neurology* 2020, 19, 591-600, doi:10.1016/s1474-4422(20)30136-8.
 78. Affitope PD01A, PD03A. Available online: <https://www.alzforum.org/therapeutics/affitope-pd01a-pd03a> (accessed on October 20, 2021).
 79. Sulzer, D.; Alcalay, R.N.; Garretti, F.; Cote, L.; Kanter, E.; Agin-Liebes, J.; Liong, C.; McMurtrey, C.; Hildebrand, W.H.; Mao, X.; et al. T cells from patients with Parkinson's disease recognize α -synuclein peptides. *Nature* 2017, 546, 656-661, doi:10.1038/nature22815.

80. Doucet, M.; El-Turabi, A.; Zabel, F.; Hunn, B.H.M.; Bengoa-Vergniory, N.; Cioroch, M.; Ramm, M.; Smith, A.M.; Gomes, A.C.; Cabral de Miranda, G.; et al. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. *PloS one* 2017, 12, e0181844, doi:10.1371/journal.pone.0181844.
81. Ghochikyan, A.; Petrushina, I.; Davtyan, H.; Hovakimyan, A.; Saing, T.; Davtyan, A.; Cribbs, D.H.; Agadjanyan, M.G. Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α -synuclein: feasibility study. *Neuroscience letters* 2014, 560, 86-91, doi:10.1016/j.neulet.2013.12.028.
82. Nelde, A.; Rammensee, H.G.; Walz, J.S. The Peptide Vaccine of the Future. *Molecular & cellular proteomics : MCP* 2021, 20, 100022, doi:10.1074/mcp.R120.002309.
83. Birmpilis, A.I.; Karachaliou, C.E.; Samara, P.; Ioannou, K.; Selemenakis, P.; Kostopoulos, I.V.; Kavrochorianou, N.; Kalbacher, H.; Livaniou, E.; Haralambous, S.; et al. Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide. *Cancers* 2019, 11, doi:10.3390/cancers11111764.
84. Zhai, P.; Ding, Y.; Wu, X.; Long, J.; Zhong, Y.; Li, Y. The epidemiology, diagnosis and treatment of COVID-19. *International journal of antimicrobial agents* 2020, 55, 105955, doi:10.1016/j.ijantimicag.2020.105955.
85. Armstrong, R.A. Risk factors for Alzheimer's disease. *Folia neuropathologica* 2019, 57, 87-105, doi:10.5114/fn.2019.85929.
86. Ogino, S.; Nowak, J.A.; Hamada, T.; Milner, D.A., Jr.; Nishihara, R. Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology. *Annual review of pathology* 2019, 14, 83-103, doi:10.1146/annurev-pathmechdis-012418-012818.
87. Willyard, C. How gut microbes could drive brain disorders. *Nature* 2021, 590, 22-25, doi:10.1038/d41586-021-00260-3.
88. Chen, S.G.; Stribinskis, V.; Rane, M.J.; Demuth, D.R.; Gozal, E.; Roberts, A.M.; Jagadapillai, R.; Liu, R.; Choe, K.; Shivakumar, B.; et al. Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and *Caenorhabditis elegans*. *Scientific reports* 2016, 6, 34477, doi:10.1038/srep34477.
89. Ashton, N.J.; Janelidze, S.; Al Khleifat, A.; Leuzy, A.; van der Ende, E.L.; Karikari, T.K.; Benedet, A.L.; Pascoal, T.A.; Lleó, A.; Parnetti, L.; et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nature communications* 2021, 12, 3400, doi:10.1038/s41467-021-23620-z.
90. Wongta, A.; Hongsibsong, S.; Chantara, S.; Pattarawarapan, M.; Saphamrer, R.; Sringarm, K.; Xu, Z.L.; Wang, H. Development of an Immunoassay for the Detection of Amyloid Beta 1-42 and

Its Application in Urine Samples. *Journal of immunology research* 2020, 2020, 8821181, doi:10.1155/2020/8821181.

91. Razzino, C.A.; Serafín, V.; Gamella, M.; Pedrero, M.; Montero-Calle, A.; Barderas, R.; Calero, M.; Lobo, A.O.; Yáñez-Sedeño, P.; Campuzano, S.; et al. An electrochemical immunosensor using gold nanoparticles-PAMAM-nanostructured screen-printed carbon electrodes for tau protein determination in plasma and brain tissues from Alzheimer patients. *Biosensors & bioelectronics* 2020, 163, 112238, doi:10.1016/j.bios.2020.112238.
92. Nakamura, A.; Kaneko, N.; Villemagne, V.L.; Kato, T.; Doecke, J.; Doré, V.; Fowler, C.; Li, Q.X.; Martins, R.; Rowe, C.; et al. High performance plasma amyloid- β biomarkers for Alzheimer's disease. *Nature* 2018, 554, 249-254, doi:10.1038/nature25456.

Retrieved from <https://encyclopedia.pub/entry/history/show/43395>